Researchers investigated cerebral small vessel disease, a precursor to dementia, by analyzing data from thousands of ...

Recently published in Neurobiology of Aging, the study demonstrates that the drug improves memory deficits and reverses brain ...

That amyloid subtype was described as a “toxic oligomer” — soluble in the fluid that bathes the brain, unlike the sticky plaques commonly associated with Alzheimer’s. The study became ...

First, genetic alterations that unequivocally cause Alzheimer’s (mutations in the amyloid protein or an enzyme called “presenilin” that creates it) have been proven to induce both the brain ...

Researchers at the University of Pittsburgh have devised a biomarker test that can spot small amounts of clumping tau protein in the brain and cerebrospinal fluid, which lead to Alzheimer's disease.

Biomarker Test Can Detect Alzheimer's Pathology Earlier Feb. 10, 2025 — Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

The Swedish biotech behind a groundbreaking Alzheimer’s treatment is in talks with partners for its new technology that allows drugs to cross the notoriously tricky blood-brain barrier.

Further, the study found when that particular bacterium crosses into the mouse brain it can trigger pathological changes that are similar to what is seen in Alzheimer's disease. Essentially that's ...